Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

C4591031- first boost
 
NCT04955626
RCTfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)low
5081/5044 conclusif
  • demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
C4591031- first boost
 
NCT04955626
RCTfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)low
5081/5044 conclusif
  • demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
Pfizer/BioNTech Booster study
 
NCT04713553
RCTfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
-/- no results
    Observed relative vaccine efficacy of 95.6% (95% CI: 89.3, 98.6). The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no safety concerns identified (press release).
    Pfizer/BioNTech Booster study
     
    NCT04713553
    RCTfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
    -/- no results
      Observed relative vaccine efficacy of 95.6% (95% CI: 89.3, 98.6). The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no safety concerns identified (press release).
      COVI3 OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
      -/- suggested
      • suggested 93 % decrease in confirmed COVID (any severity) (PE)
      • suggested 93 % decrease in symptomatic Covid-19
      COVI3 OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
      -/- suggested
      • suggested 93 % decrease in confirmed COVID (any severity) (PE)
      • suggested 93 % decrease in symptomatic Covid-19
      McConeghy OBSfirst booster dosemRNA vaccineCOVID-19 prophylaxis (excluding children)NA
      -/- suggested
      • suggested 97 % decrease in deaths,deaths
      • suggested 82 % decrease in hospitalization or death,hospitalization or death
      • suggested 51 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      • suggested 58 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      McConeghy OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
      -/- suggested
      • suggested 97 % decrease in deaths,deaths
      • suggested 82 % decrease in hospitalization or death,hospitalization or death
      • suggested 51 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      • suggested 58 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      Thompson OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)critical
      2961/989 suggested
      • suggested 90 % decrease in confirmed COVID (any severity) but with a very low degree of certainty due to critical risk of bias
      Agur unpublished OBSmRNA vaccineuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
      -/- no results
        Kislaya OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
        -/- suggested
        • suggested 69 % decrease in confirmed COVID (any severity)
        • suggested 64 % decrease in confirmed COVID (any severity)
        Kislaya OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
        -/- suggested
        • suggested 69 % decrease in confirmed COVID (any severity)
        Kislaya OBSfirst booster doseVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)COVID-19 prophylaxis (excluding children)NA
        -/- suggested
        • suggested 64 % decrease in confirmed COVID (any severity)
        Bar-On OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
        -/- suggested
        • suggested 91 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
        Bar-On OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
        -/- suggested
        • suggested 91 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
        Shemer OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
        -/- inconclusive
          Accorsi OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
          -/- no results
            Comparison of 2 Doses vs Unvaccinated by Time Since Vaccination (graphical presentation) : The upper bound of the 95% CI was consistently greater than 1 starting at 3 months after second dose for BNT162b2 and at 6 months after second dose for mRNA-1273
            Accorsi OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
            -/- no results
              Comparison of 2 Doses vs Unvaccinated by Time Since Vaccination (graphical presentation) : The upper bound of the 95% CI was consistently greater than 1 starting at 3 months after second dose for BNT162b2 and at 6 months after second dose for mRNA-1273
              Thompson -VISIOn Network (omicron) OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
              -/- suggested
              • suggested 81 % decrease in hospitalization
              • suggested 52 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
              Thompson -VISIOn Network (omicron) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
              -/- suggested
              • suggested 90 % decrease in hospitalization
              • suggested 82 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
              UKHSA report week 12 (24 March 2022) OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
              -/- no results
                UKHSA report week 12 (24 March 2022) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                -/- suggested
                • suggested 88 % decrease in deaths,deaths (time to event analysis only)
                • suggested 83 % decrease in hospitalization
                Abu-Raddad OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
                -/- suggested
                • suggested 77 % decrease in hospitalization or death
                • suggested 49 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
                • suggested 47 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
                Abu-Raddad OBSfirst booster doseSpikevax (Moderna mRNA-1273 COVID-19 vaccine)COVID-19 prophylaxis (excluding children)NA
                -/- suggested
                • suggested 47 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
                Abu-Raddad OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
                -/- suggested
                • suggested 77 % decrease in hospitalization or death
                • suggested 49 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
                Kirsebom (UKHSA) OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                -/- suggested
                • suggested 17 % decrease in symptomatic Covid-19
                Arbel OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)serious
                758118/85090 suggested
                • suggested 90 % decrease in deaths,deaths (PE) but with a low degree of certainty due to high risk of bias
                Arbel OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)serious
                758118/85090 suggested
                • suggested 90 % decrease in deaths,deaths (PE) but with a low degree of certainty due to high risk of bias
                Barda OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
                728321/728321 suggested
                • suggested 81 % decrease in deaths
                • suggested 93 % decrease in hospitalization (PE)
                Barda OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
                728321/728321 suggested
                • suggested 81 % decrease in deaths
                • suggested 93 % decrease in hospitalization (PE)
                CDC Mesa County, Colorado OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                -/- suggested
                • suggested 78 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
                HEROES-RECOVER (Fowlkes) OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                3483/734 suggested
                  Martinez-Baz OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
                  -/- suggested
                  • suggested 82 % decrease in confirmed COVID (any severity)
                  • suggested 95 % decrease in hospitalization,severe COVID-19 occurrence
                  • suggested 82 % decrease in symptomatic Covid-19
                  Pawlowski OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
                  31069/31069 suggested
                    Pawlowski OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
                    -/- inconclusive
                      REACT-1 round 13 final report (Elliott, Imperial College London) OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                      -/- suggested
                      • suggested 59 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
                      Shah OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                      -/- suggested
                      • suggested 55 % decrease in confirmed COVID (any severity) but with a low degree of certainty due to high risk of bias
                      Shibli OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                      -/- safety concern
                      • statistically significant 36 % increase in Bell's palsy
                      Tande unpublished OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                      -/- no results
                        Mattiuzzi OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 85 % decrease in confirmed COVID (any severity)
                        • suggested 85 % decrease in hospitalization
                        Mattiuzzi OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 65 % decrease in confirmed COVID (any severity)
                        • suggested 69 % decrease in hospitalization
                        Lauring OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                        5728/5962 suggested
                        • suggested 44 % decrease in death or ventilation
                        • suggested 46 % decrease in death or ventilation
                        • suggested 76 % decrease in death or ventilation
                        • suggested 85 % decrease in hospitalization
                        • suggested 85 % decrease in hospitalization
                        • suggested 65 % decrease in hospitalization
                        Lauring OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                        5728/5962 suggested
                        • suggested 86 % decrease in hospitalization
                        Lauring OBSfirst booster dosemRNA vaccineCOVID-19 prophylaxis (excluding children)NA
                        5728/5962 suggested
                        • suggested 94 % decrease in hospitalization
                        Lauring OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
                        5728/5962 suggested
                        • suggested 94 % decrease in hospitalization
                        Ontario (Buchan) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 37 % decrease in confirmed COVID (any severity)
                        Patalon OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 85 % decrease in confirmed COVID (any severity)
                        • suggested 92 % decrease in hospitalization
                        Patalon OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 85 % decrease in confirmed COVID (any severity)
                        • suggested 92 % decrease in hospitalization
                        Tenforde OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 82 % decrease in confirmed COVID (any severity)
                        Tenforde OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 97 % decrease in confirmed COVID (any severity)
                        Tenforde OBSfirst booster dosemRNA vaccineCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 82 % decrease in hospitalization
                        Tenforde OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 82 % decrease in hospitalization
                        Butt OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)moderate
                        54360/54360 suggested
                        • suggested 97 % decrease in confirmed COVID (any severity) with a moderate degree of certainty due to some concern in risk of bias
                        Chung OBSmRNA vaccinecontrolCOVID-19 prophylaxis (excluding children)NA
                        53270/270763 suggested
                        • suggested 91 % decrease in symptomatic Covid-19
                        England (Andrews) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                        581/130867 suggested
                        • suggested 75 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
                        • suggested 71 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
                        Grannis OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                        -/- suggested
                        • suggested 82 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
                        Li OBSInactivated virus vaccinecontrolCOVID-19 prophylaxis (excluding children)critical
                        74/292 suggested
                        • suggested 59 % decrease in confirmed COVID (any severity) but with a very low degree of certainty due to critical risk of bias
                        Patalon OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 79 % decrease in confirmed COVID (any severity)
                        Patalon OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 79 % decrease in confirmed COVID (any severity)
                        REACT-SCOT OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)NA
                        111295/1093449 suggested
                        • suggested 61 % decrease in hospitalization or death
                        Sisonke 2 (booster)
                         
                        NCT05148845
                        OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
                        -/- suggested
                        • suggested 85 % decrease in hospitalization
                        VA (Bajema) OBSvaccinescontrolCOVID-19 prophylaxis (excluding children)serious
                        -/- suggested
                          Aleman DESCmRNA vaccineuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
                          -/- no results
                            Boyarsky DESCmRNA vaccineuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
                            -/- no results
                              Boyarsky DESCvaccinesuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
                              -/- no results

                                PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                                Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).